This would definitely confirm the involvement of such FOXO3-dependent autophagy in the refractoriness to sorafenib of resistant HCC cells, also verifying for the first time the beneficial modulatory action of regorafenib on this chemoresistant mechanism. The gene discussed is FOXO3; the disease is hepatocellular carcinoma.